Schroder Investment Management Group
KROS icon

Schroder Investment Management Group’s Keros Therapeutics KROS Stock Holding History

Schroder Investment Management Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,917
Closed -$254K – 1230
2023
Q3 		$254K Buy
+7,917
New +$296K ﹤0.01% 1154
2023
Q2 		– Sell
-7,066
Closed -$298K – 1259
2023
Q1 		$298K Buy
+7,066
New +$357K ﹤0.01% 1182

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schroder Investment Management Group's KROS Position: Q4 2023 in Review

Schroder Investment Management Group sold out of Keros Therapeutics (KROS) in Q4 2023, closing a stake of 7,917 shares — an estimated $254K sold.

Schroder Investment Management Group first reported a position in KROS in Q1 2023 and held it in 2 quarters. The position peaked at $298K in Q1 2023. 121 funds tracked by Wall St. Rank hold KROS as of Q4 2023.

  • Schroder Investment Management Group reported no remaining Keros Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Schroder Investment Management Group sold 7,917 Keros Therapeutics shares in Q4 2023, an estimated $254K.
  • Schroder Investment Management Group first reported a position in Keros Therapeutics in Q1 2023 and held it in 2 quarters.
  • Schroder Investment Management Group's Keros Therapeutics position peaked at $298K in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2023.

Based on Schroder Investment Management Group's 13F filing for Q4 2023, filed 14 Feb 2024.